Canada's broad Can$400m venture capital plan expected to help biotech
This article was originally published in Scrip
Canadian Prime Minister Stephen Harper unveiled a Venture Capital Action Plan on 14 January that will see the country's government investing Can$400 million in venture capital for high-growth companies in order to create jobs, but the money will be distributed across Canada's provinces and various industries, including biotechnology.
You may also be interested in...
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality.
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.